Ara
Toplam kayıt 6, listelenen: 1-6
Seldi-tof-ms profiling of metastatic phenotype in histopathological subtypes of breast cancer
(Bentham Science Publishers Ltd, 2018)
Background: Early detection of breast cancer is a key to the success of breast cancer management. Serum proteome analysis using Surface-Enhanced Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry (SELDI-TOF-MS) ...
Biological evaluation of imidazopyridine derivatives as potential anticancer agents against breast cancer cells
(Springer, 2022)
Imidazo[1,2-a]pyridine cores have increasing importance in the pharmaceutical industry with their wide range pharmacological activities. In this study, two series of imidazopyridine derivatives were synthesized. It was ...
The role of 18F-FDG PET/CT in predicting the neoadjuvant treatment response in patients with locally advanced breast cancer
(Karger, 2022)
Purpose: Patients with locally advanced breast cancer (LABC) should be treated with neoadjuvant chemotherapy (NAC). Pathological complete response (pCR) is related to better disease-free survival (DFS). The best strategy ...
Chitosan modification-enhanced silencing effect of Ad5-shPDGF-D vector in breast cancer cell line MDA-MB-231
(Bentham Science Publishers, 2023)
Background: Gene therapeutics are being developed to treat metastatic breast tumors, which are mostly resistant to conventional therapies. Targeting platelet-derived growth factor-D (PDGF-D) is a viable approach because ...
Association of tumor strain ratio with prognostic factors in invasive breast cancer
(Springer, 2022)
We evaluate the correlations between tumor strain ratio value and prognostic factors for breast cancers. Fifty-seven women with invasive breast cancer underwent ultrasound elastography prior to surgery. Elastography strain ...
Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study
(2024)
Background: Triple negative breast cancer (TNBC) is characterized by high rates of recurrence, especially in patients with residual disease after neoadjuvant chemotherapy (NAC). Capecitabine is being used as standard ...